Haemolytic uraemic syndrome

Area of Science:

• Nephrology
• Hematology
• Immunology

Background:

• Haemolytic uraemic syndrome (HUS) is a critical condition characterized by nonimmune hemolytic anemia, thrombocytopenia, and acute renal failure.
• It involves thrombotic microangiopathy, primarily affecting the kidneys but also other organs, linked to endothelial cell injury and platelet activation.

Purpose of the Study:

• To review the diverse causes, clinical and pathological features, epidemiology, and pathogenetic mechanisms of HUS.
• To detail the diagnostic investigations, including biochemical, microbiological, immunological, and genetic approaches.
• To highlight how understanding HUS subtypes informs tailored treatment and management strategies.

Main Methods:

• Comprehensive review of existing literature on Haemolytic uraemic syndrome.
• Analysis of clinical, pathological, hematological, biochemical, microbiological, immunological, and genetic data.
• Synthesis of information on pathogenetic mechanisms and diagnostic criteria for HUS subtypes.

Main Results:

• Most HUS cases are linked to Shiga toxin-producing enterohaemorrhagic Escherichia coli (EHEC) infections.
• Atypical HUS (aHUS) is associated with complement dysregulation, often due to genetic mutations or autoantibodies.
• No specific treatment exists for EHEC-HUS, requiring supportive care, while aHUS patients benefit from anti-C5 antibody therapy.

Conclusions:

• Understanding the distinct mechanisms of HUS subtypes is crucial for effective patient management.
• Supportive care is standard for EHEC-associated HUS.
• Anti-C5 antibody treatment offers a targeted approach for aHUS, preventing recurrence post-transplant.